Takeda Pharmaceutical Co. has decided to terminate development of fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. The company has worked with three independent panels regarding safety oversight, including the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program.
Following a review of the data emerging from all the clinical trials and in consultation with these panels, the company has decided that the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks, and has decided to voluntarily terminate development activities for fasiglifam.
Takeda Terminates Fasiglifam Development
By Kristin Brooks
Published December 30, 2013
blog comments powered by Disqus